Abstract
Activation of the trptophan catabolite (TRYCAT) pathways by oxidative and nitrosative stress and proinflammatory cytokine-driven indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) leads to the synthesis of a number of neuroregulatory TRYCATs, such as kynurenic acid and quinolinic acid. Such TRYCATs have significant impacts on neuronal functioning and survival contributing to the changes seen in Alzheimer's disease (AD), including in its association with depression as well as alterations in the reactivity of immune and glia cells.
By decreasing the availability of tryptophan for serotonin synthesis, such IDO and TDO-driven TRYCATs, also decrease the availability of serotonin for N-acetylserotonin (NAS) and melatonin synthesis. The loss of NAS and melatonin has significant consequences for the etiology, course and treatment of AD, including via interactions with altered TRYCATs, but also by changing the levels of trophic support and modulating the patterning of immune activity.
In this review, we look at how such interactions of the TRYCAT and melatoninergic pathways link a plethora of previously diffuse data in AD as well as the treatment implications and future research directions that such data would suggest.
Keywords: Tryptophan catabolites, melatonin, N-acetylserotonin, Alzheimer's disease, inflammation, oxidative stress, nitrosative stress, treatment, glia, immunity, pineal, mitochondria, sirtuins.
Current Pharmaceutical Design
Title:Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Volume: 22 Issue: 8
Author(s): Michael Maes and George Anderson
Affiliation:
Keywords: Tryptophan catabolites, melatonin, N-acetylserotonin, Alzheimer's disease, inflammation, oxidative stress, nitrosative stress, treatment, glia, immunity, pineal, mitochondria, sirtuins.
Abstract: Activation of the trptophan catabolite (TRYCAT) pathways by oxidative and nitrosative stress and proinflammatory cytokine-driven indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) leads to the synthesis of a number of neuroregulatory TRYCATs, such as kynurenic acid and quinolinic acid. Such TRYCATs have significant impacts on neuronal functioning and survival contributing to the changes seen in Alzheimer's disease (AD), including in its association with depression as well as alterations in the reactivity of immune and glia cells.
By decreasing the availability of tryptophan for serotonin synthesis, such IDO and TDO-driven TRYCATs, also decrease the availability of serotonin for N-acetylserotonin (NAS) and melatonin synthesis. The loss of NAS and melatonin has significant consequences for the etiology, course and treatment of AD, including via interactions with altered TRYCATs, but also by changing the levels of trophic support and modulating the patterning of immune activity.
In this review, we look at how such interactions of the TRYCAT and melatoninergic pathways link a plethora of previously diffuse data in AD as well as the treatment implications and future research directions that such data would suggest.
Export Options
About this article
Cite this article as:
Maes Michael and Anderson George, Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease, Current Pharmaceutical Design 2016; 22 (8) . https://dx.doi.org/10.2174/1381612822666151214125804
DOI https://dx.doi.org/10.2174/1381612822666151214125804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combining Feature Extraction Methods to Assist the Diagnosis of Alzheimer’s Disease
Current Alzheimer Research New Approaches for Antithrombotic Antiplatelet Therapies
Current Medicinal Chemistry Smoking and Cognition
Current Drug Abuse Reviews Ameliorative Effects of Baicalein on an Amyloid-β Induced Alzheimer's Disease Rat Model: A Proteomics Study
Current Alzheimer Research Complex Interactions between Phytochemicals. The Multi-Target Therapeutic Concept of Phytotherapy
Current Drug Targets Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Cardiac Amyloid - A Hidden Contributor to Cardiac Dysfunction Following Cardiac Surgery: Case Report and Literature Review
Current Cardiology Reviews Meet the Editorial Board
Current Alzheimer Research Predicting Progression from Cognitive Impairment to Alzheimer’s Disease with the Disease State Index
Current Alzheimer Research Pomegranate Extract Modulates Processing of Amyloid-β Precursor Protein in an Aged Alzheimer`s Disease Animal Model
Current Alzheimer Research Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Geriatric Depression - Review for Primary Care
Current Psychiatry Reviews Editorial: Glia-Neuron Crosstalk and its Therapeutic Implication in Neuropsychiatric Disorders
Current Neuropharmacology Age-Related Sleep Disruption and Reduction in the Circadian Rhythm of Urine Output: Contribution to Nocturia?
Current Aging Science Is Formaldehyde the Missing Link in AD Pathology? The Differential Aggregation of Amyloid-Beta with APOE Isoforms In Vitro
Current Alzheimer Research Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Drugs for AIDS
Mini-Reviews in Medicinal Chemistry The Relationship Between Hypertensive Retinopathy and Angiotensin Converting Enzyme Gene Polymorphism
Cardiovascular & Hematological Disorders-Drug Targets